What is WO2013171639 (and what does it cover)?
WO2013171639 is a PCT (Patent Cooperation Treaty) publication published in 2013 that is commonly associated with invention disclosures around asciminib. Asciminib is the active ingredient in the BCR-ABL inhibitor marketed as Scemblix, and WO publications like this one typically describe the underlying compounds/structures, how they work, and how they can be made and used.
If you want to see the exact claims and examples, you can open the record directly on Google Patents using the publication number.
Where to find it on Google Patents
On Google Patents, search by publication number: WO2013171639.
- Google Patents search: https://patents.google.com/?q=WO2013171639
From that page you can usually view: assignee/applicant data, claim language, cited references, and related family members (other jurisdictions that contain the same core invention).
How to check if this is a “Scemblix/asciminib” patent or a different filing in the same family
Publication numbers often map to patent families that include multiple country filings. To confirm relevance to asciminib, check on the Google Patents page for:
- “Inventor” and “Assignee” names linked to asciminib development
- Use of terms like “asciminib,” “ABL,” or the specific chemical class described in the document
- The claim set—especially product claims (compound structures) versus method-of-use claims
Is there a related patent expiration or exclusivity timeline for WO2013171639?
To determine expiration (and whether it affects Scemblix exclusivity), you need to identify:
- The priority date for the family
- The specific jurisdictions where it entered (US, EP, JP, etc.)
- Whether later adjustments, exclusivity extensions, or term changes apply
DrugPatentWatch.com can help you connect a patent family to drug-specific status and timetables when available. (If you share the assignee names or the country family members you care about, I can help interpret the timeline.)
Source: DrugPatentWatch.com (patent/drug timelines and linkages): https://www.drugpatentwatch.com/
Who is the assignee/inventor, and how can that help you find the enforcement or licensing risk?
Enforcement risk usually tracks the assignee that controls enforcement in each country. On the Google Patents page for WO2013171639, look for:
- Legal status indicators (if present)
- “Current Assignee” / “Original Assignee”
- Family members and any events listed for each jurisdiction
Those details let you map whether it’s held by the same company commercializing asciminib or by another entity with overlapping claims.
If you paste the Google Patents link, I can summarize the exact claims
If you share the URL you land on (or paste the assignee and priority date shown on Google Patents), I can translate the document into plain language: what the patent claims, what it protects (compound vs method), and how that typically interacts with drug protection around asciminib.
Sources
1. https://patents.google.com/?q=WO2013171639
2. https://www.drugpatentwatch.com/